var data={"title":"Flumazenil: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Flumazenil: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6207?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=flumazenil-drug-information\" class=\"drug drug_general\">see &quot;Flumazenil: Drug information&quot;</a> and <a href=\"topic.htm?path=flumazenil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Flumazenil: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708776\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Seizures:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The use of flumazenil has been associated with the occurrence of seizures. These are most frequent in patients who have been on benzodiazepines for long-term sedation or in overdose cases where patients are showing signs of serious cyclic antidepressant overdose. Practitioners should individualize the dosage of flumazenil and be prepared to manage seizures.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172028\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Anexate;</li>\n      <li>Flumazenil Injection;</li>\n      <li>Flumazenil Injection, USP;</li>\n      <li>Romazicon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052814\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Benzodiazepine</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12674641\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzodiazepine reversal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: <b>Note:</b> Minimal information available; dosing is extrapolated from experiences in pediatric patients 1-17 years; Initial dose: 0.01 mg/kg given over 15 seconds; may repeat 0.01 mg/kg after 45 seconds, and then every minute to a maximum total cumulative dose of 0.05 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion (as an alternative to repeat bolus doses): 0.005-0.01 mg/kg/<b>hour</b>; dose based on a case report of premature neonate (GA: 32 weeks) exposed to high doses of diazepam intrapartum (Dixon, 1998) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Myoclonus, benzodiazepine-induced: IV: 0.0078 mg/kg as a single dose was effective in one full-term neonate who was receiving continuous infusion midazolam (Zaw, 2001) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052806\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=flumazenil-drug-information\" class=\"drug drug_general\">see &quot;Flumazenil: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Benzodiazepine reversal when used in conscious sedation or general anesthesia:</b> Infants, Children, and Adolescents: IV: Initial dose: 0.01 mg/kg (maximum dose: 0.2 mg) given over 15 seconds; may repeat 0.01 mg/kg (maximum dose: 0.2 mg) after 45 seconds, and then every minute to a maximum total cumulative dose of 0.05 mg/kg or 1 mg, whichever is lower; usual total dose: 0.08 to 1 mg (mean: 0.65 mg) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Suspected benzodiazepine overdose:</b> Limited data available: Infants, Children, and Adolescents: Initial dose: 0.01 mg/kg (maximum dose: 0.2 mg) with repeat doses of 0.01 mg/kg (maximum dose: 0.2 mg) given every minute to a maximum total cumulative dose of 1 mg; as an alternative to repeat bolus doses, follow up continuous infusions of 0.005-0.01 mg/kg/<b>hour</b> have been used (Clark 1995; Richard 1991; Roald 1989; Sugarman 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Benzodiazepine reversal when used in conscious sedation or general anesthesia:</b> 0.2 mg given over 15 seconds; may repeat 0.2 mg after 45 seconds and then every 60 seconds up to a total of 1 mg, usual total dose: 0.6 to 1 mg. In event of resedation, may repeat doses at 20-minute intervals with maximum of 1 mg/dose (given at 0.2 mg/minute); maximum dose: 3 mg in 1 hour. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Management of benzodiazepine overdose:</b> 0.2 mg over 30 seconds; may give 0.3 mg dose after 30 seconds if desired level of consciousness is not obtained; additional doses of 0.5 mg can be given over 30 seconds at 1-minute intervals up to a cumulative dose of 3 mg; usual cumulative dose: 1 to 3 mg; rarely, patients with partial response at 3 mg may require additional titration up to total dose of 5 mg; if patient has not responded 5 minutes after cumulative dose of 5 mg, the major cause of sedation is not likely due to benzodiazepines. In the event of resedation, may repeat doses at 20-minute intervals with maximum of 1 mg/dose (given at 0.5 mg/minute); maximum dose: 3 mg in 1 hour. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Initial dose: Use normal dose; repeat doses should be decreased in size or frequency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172006\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg/5 mL (5 mL); 1 mg/10 mL (10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171991\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052818\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: For IV use only; administer by rapid IV injection over 15-30 seconds via a freely running IV infusion into larger vein (to decrease chance of pain, phlebitis). Children: Do not exceed 0.2 mg/minute. Adults: Repeat doses: Do not exceed 0.2 mg/minute for reversal of general anesthesia and do not exceed 0.5 mg/minute for reversal of benzodiazepine overdose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172022\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Once drawn up in the syringe or mixed with D5W, LR, or NS, use within 24 hours. Discard any unused solution after 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052817\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Benzodiazepine antagonist; reverses sedative effects of benzodiazepines used in general anesthesia or conscious sedation; management of benzodiazepine overdose; <b>not indicated</b> for ethanol, barbiturate, general anesthetic or opioid overdose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7914344\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Flumazenil may be confused with influenza virus vaccine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172077\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing, palpitation, thrombophlebitis, vasodilatation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, anxiety, ataxia, depersonalization, depression, dizziness, dysphoria, emotional lability (including crying), euphoria, fatigue, headache, hypoesthesia, insomnia, malaise, nervousness, paranoia, paresthesia. vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermatological disease (skin abnormality), diaphoresis, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hot flash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, lacrimation, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, hyperventilation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Atrial tachycardia (paroxysmal), auditory disturbance, bradycardia, cardiac arrhythmia, chest pain, confusion, decreased blood pressure, delirium, drowsiness, fear, hiccups, hyperacusis, hypertension, increased blood pressure, lack of concentration, panic attack, reversible hearing loss, rigors, seizure (including generalized), sensation of cold, shivering, stupor, tachycardia, tinnitus, tongue edema, ventricular tachycardia, voice disorder, withdrawal syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172012\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to flumazenil, benzodiazepines, or any component of the formulation; patients given benzodiazepines for control of potentially life-threatening conditions (eg, control of intracranial pressure or status epilepticus); patients who may have ingested or are showing signs of cyclic-antidepressant overdosage.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171995\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Amnesia: Does not consistently reverse amnesia; patient may not recall verbal instructions after procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving) for 24 hours after discharge.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Resedation: Occurs more frequently in patients where a large single dose or cumulative dose of a benzodiazepine has been administered along with a neuromuscular-blocking agent and multiple anesthetic agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: Should not rely upon to reverse respiratory depression/hypoventilation. Flumazenil is not a substitute for evaluation of oxygenation. Establishing an airway and assisting ventilation, as necessary, is always the initial step in overdose management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: <b>[US Boxed Warning]: Benzodiazepine reversal may result in seizures; seizures may occur more frequently in patients on benzodiazepines for long-term sedation or following tricyclic antidepressant overdose. Dose should be individualized and practitioners should be prepared to manage seizures.</b> Seizures may also develop in patients with concurrent major sedative-hypnotic drug withdrawal, recent therapy with repeated doses of parenteral benzodiazepines, myoclonic jerking or seizure activity prior to flumazenil administration. Use with caution in patients relying on a benzodiazepine for seizure control.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head injury: Use with caution in patients with a head injury; may alter cerebral blood flow or precipitate convulsions in patients receiving benzodiazepines.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic dysfunction; repeated doses of the drug should be reduced in frequency or amount.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Panic disorder: Use with caution in patients with a history of panic disorder; may provoke panic attacks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug/alcohol dependence: Use caution in drug and ethanol-dependent patients; these patients may also be dependent on benzodiazepines.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intensive care patients: Should be used with caution in the intensive care unit because of increased risk of unrecognized benzodiazepine dependence in such settings.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Should not be used to diagnose benzodiazepine-induced sedation. Reverse neuromuscular blockade before considering use. Flumazenil does not antagonize the CNS effects of other GABA agonists (such as ethanol, barbiturates, or general anesthetics); nor does it reverse opioids. Not recommended for treatment of benzodiazepine dependence.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Overdose use: Use with caution in patients with mixed drug overdoses; toxic effects of other drugs taken may emerge once benzodiazepine effects are reversed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25820048\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Pediatric patients (especially 1 to 5 years of age) may experience resedation; these patients may require repeat bolus doses or continuous infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299345\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172000\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13307&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Hypnotics (Nonbenzodiazepine): Flumazenil may diminish the sedative effect of Hypnotics (Nonbenzodiazepine). <b> Exceptions: </b>Ramelteon; Suvorexant; Tasimelteon.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172002\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172014\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects were not seen in animal reproduction studies. Embryocidal effects were seen at large doses. Use during labor and delivery is not recommended. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052813\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Level of consciousness and resedation, blood pressure, heart rate, respiratory rate, continuous pulse oximetry; monitor for resedation for 1-2 hours after reversal of sedation in patients who receive benzodiazepine sedation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171994\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitively inhibits the activity at the benzodiazepine receptor site on the GABA/benzodiazepine receptor complex. Flumazenil does not antagonize the CNS effect of drugs affecting GABA-ergic neurons by means other than the benzodiazepine receptor (ethanol, barbiturates, general anesthetics) and does not reverse the effects of opioids</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172011\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Follows a two compartment open model; Clearance and V<sub>d</sub> per kg are similar for children and adults, but children display more variability </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 1-2 minutes; 80% response within 3 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: 6-10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Resedation occurs after ~1 hour (range: 19-50 minutes); duration related to dose given and benzodiazepine plasma concentrations; reversal effects of flumazenil may wear off before effects of benzodiazepine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Initial V<sub>d</sub>: 0.5 L/kg; V<sub>dss</sub>: 0.9-1.1 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~50% (~67% of which is bound to albumin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; dependent upon hepatic blood flow</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: Terminal: 20-75 minutes (mean: 40 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Alpha: 4-11 minutes; Terminal: 40-80 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Moderate hepatic dysfunction: 1.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Severe hepatic impairment: 2.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces; urine (&lt;1% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Dependent upon hepatic blood flow; Adults: 0.8-1 L/hour/kg </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052823\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Flumazenil is a weak lipophilic base. In one study of conscious sedation reversal in 107 pediatric patients (1-17 years of age), resedation occurred between 19-50 minutes after the start of flumazenil. Flumazenil has been used to successfully treat paradoxical reactions in children associated with midazolam use (eg, agitation, restlessness, combativeness) (Massanari, 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323156\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Flumazenil Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/5 mL (5 mL): $7.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/10 mL (10 mL): $148.31</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172015\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anexate (AE, AT, AU, BE, BF, BG, BH, BJ, CH, CI, CN, CY, CZ, DE, EE, EG, ES, ET, FR, GH, GM, GN, GR, HK, HR, HU, ID, IE, IL, IQ, IR, IT, JO, JP, KE, KR, KW, LB, LK, LR, LU, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, OM, PK, PL, PT, QA, RO, SA, SC, SD, SI, SK, SL, SN, SY, TN, TR, TW, TZ, UG, VN, YE, ZA, ZM, ZW);</li>\n      <li>Antabenz (MY);</li>\n      <li>Antadona (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Anzenil (PH);</li>\n      <li>Fadaflumaz (AR);</li>\n      <li>Flumage (AR);</li>\n      <li>Flumazen (AU);</li>\n      <li>Flumil (PY, UY);</li>\n      <li>Flunexate (JO, LB);</li>\n      <li>Flunexil (BR);</li>\n      <li>Flunil (KR);</li>\n      <li>Fluoxem (CL);</li>\n      <li>Lai Yi (CN);</li>\n      <li>Lanexat (BB, BM, BR, BS, BZ, CL, CO, CR, DK, DO, EC, FI, GT, GY, HN, JM, MX, NI, PA, PE, PY, SE, SR, SV, TT, UY, VE);</li>\n      <li>Outnestin (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baktai G, Szekely E, Marialigeti T, et al, &ldquo;Use of Midazolam (Dormicum) and Flumazenil (Anexate) in Paediatric Bronchology,&rdquo; <i>Curr Med Res Opin</i>, 1992, 12(9):552-9. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/1582237 /pubmed\" target=\"_blank\" id=\"1582237 \">1582237 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark RF, Sage TA, Tunget C, et al, &ldquo;Delayed Onset Lorazepam Poisoning Successfully Reversed By Flumazenil in a Child: Case Report and Review of the Literature,&rdquo; <i>Pediatr Emerg Care</i>, 1995, 11(1):32-4. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/7739960/pubmed\" target=\"_blank\" id=\"7739960\">7739960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dixon JC, Speidel BD, and Dixon JJ, &quot;Neonatal Flumazenil Therapy Reverses Maternal Diazepam,&quot; <i>Acta Paediatr</i>, 1998, 87(2):225-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/9512213/pubmed\" target=\"_blank\" id=\"9512213\">9512213</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones RD, Lawson AD, Andrew LJ, et al, &ldquo;Antagonism of the Hypnotic Effect of Midazolam in Children: A Randomized, Double Blind Study of Placebo and Flumazenil Administered After Midazolam-Induced Anaesthesia,&rdquo; <i>Br J Anaesth</i>, 1991, 66(6):660-6. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/2064881/pubmed\" target=\"_blank\" id=\"2064881\">2064881</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Massanari M, Novitsky J, and Reinstein LJ, &ldquo;Paradoxical Reactions in Children Associated With Midazolam Use During Endoscopy,&rdquo; <i>Clin Pediatr</i>, 1997, 36(12):681-4. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/9415834/pubmed\" target=\"_blank\" id=\"9415834\">9415834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richard P, Autret E, Bardol J, et al, &ldquo;The Use of Flumazenil in a Neonate,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1991, 29(1):137-40. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/2005661/pubmed\" target=\"_blank\" id=\"2005661\">2005661</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roald OK and Dahl V, &ldquo;Flunitrazepam Intoxication in a Child Successfully Treated With the Benzodiazepine Antagonist Flumazenil,&rdquo; <i>Crit Care Med</i>, 1989, 17(12):1355-6. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/2512053/pubmed\" target=\"_blank\" id=\"2512053\">2512053</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shannon M, Albers G, Burkhart K, et al, &ldquo;Safety and Efficacy of Flumazenil in the Reversal of Benzodiazepine-Induced Conscious Sedation. The Flumazenil Pediatric Study Group,&rdquo; <i>J Pediatr</i>, 1997, 131(4):582-6. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/9386663/pubmed\" target=\"_blank\" id=\"9386663\">9386663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sugarman JM and Paul RI, &ldquo;Flumazenil: A Review,&rdquo; <i>Pediatr Emerg Care</i>, 1994, 10(1):37-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/8177806/pubmed\" target=\"_blank\" id=\"8177806\">8177806</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zaw W, Knoppert DC, and da Silva O, &quot;Flumazenil's Reversal of Myoclonic-Like Movements Associated With Midazolam in Term Newborns,&quot; <i>Pharmacotherapy</i>, 2001, 21(5):642-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/11349753/pubmed\" target=\"_blank\" id=\"11349753\">11349753</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13307 Version 114.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708776\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F172028\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1052814\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12674641\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1052806\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F172006\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F171991\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1052818\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F172022\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1052817\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7914344\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F172077\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F172012\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F171995\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25820048\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299345\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F172000\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F172002\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F172014\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1052813\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F171994\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F172011\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1052823\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323156\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F172015\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13307|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=flumazenil-drug-information\" class=\"drug drug_general\">Flumazenil: Drug information</a></li><li><a href=\"topic.htm?path=flumazenil-patient-drug-information\" class=\"drug drug_patient\">Flumazenil: Patient drug information</a></li></ul></div></div>","javascript":null}